ADMA Biologics (ADMA): Firm Updates 2025 Revenue Guidance

Company Overview - ADMA Biologics, Inc. is a biopharmaceutical company that develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally [4]. Product Portfolio - The company markets BIVIGAM, an intravenous immune globulin product for treating primary humoral immunodeficiency, and Nabi-HB, a human polyclonal antibody product for acute exposure to blood containing Hepatitis B surface antigen [2][4]. Financial Performance - In the third quarter of 2025, ADMA Biologics updated its revenue guidance for 2025, now expecting total revenue of $510 million, an increase from the previous guidance of over $500 million [3]. - The adjusted net income for 2025 was also revised to $158 million, reflecting a higher effective tax rate [3].